Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Adbry (tralokinumab-ldrm) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical therapies or when those therapies are not advisable. Adbry can be used with or without topical corticosteroids.
• This summary is based on the review of 17 systematic review(s)/meta-analysis(es). ^[1-17]
• Efficacy Outcomes: Tralokinumab showed lower odds of achieving EASI 50 (OR 0.4, 95% CrI 0.3-0.6) compared to dupilumab, with similar results observed for EASI 75, EASI 90, and IGA success.
• Dermatology Life Quality Index (DLQI): Tralokinumab with TCS demonstrated a significantly larger improvement in DLQI compared to dupilumab with TCS (-12.1 vs -10.4, p=0.005).
• Long-Term Efficacy: Tralokinumab provided sustained improvement in EASI-50, EASI-75, EASI-90, and IGA 0/1 over one year.
• Comparative Efficacy: Tralokinumab was less effective than upadacitinib and abrocitinib in achieving EASI-50, EASI-75, and EASI-90, both in monotherapy and combination therapy contexts.
• Tralokinumab was associated with a higher incidence of conjunctivitis compared to placebo (7.5% vs. 3.2%) and was generally well-tolerated with mild and transient adverse events.
• Both tralokinumab and dupilumab exhibited similar safety profiles, but tralokinumab showed a higher incidence of conjunctivitis.
• JAK inhibitors, such as upadacitinib and abrocitinib, were linked to a higher incidence of herpes zoster compared to tralokinumab, dupilumab, and placebo.
• Tralokinumab is effective and safe for adults with moderate-to-severe atopic dermatitis (AD), but presents a higher risk of conjunctivitis in patients with more severe baseline AD and those with a history of allergic conjunctivitis or atopic keratoconjunctivitis.